TSX:IN
OTCQX:IMLFF
VANCOUVER, March 12, 2019 /CNW/ - InMed Pharmaceuticals
Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a
biopharmaceutical company developing a proprietary biosynthesis
platform technology for the manufacturing of pharmaceutical-grade
cannabinoids as well as a R&D pipeline of medications targeting
diseases with high unmet medical needs, today announced that
InMed's President and Chief Executive Officer, Eric A. Adams, will be presenting on a panel
discussion entitled "Cannabinoid Pharmaceuticals" at the
31st Annual ROTH Conference on Tuesday, March 19, 2019, at 10:00 AM PT, in Orange
County, California.
About InMed:
InMed Pharmaceuticals is a
biopharmaceutical company developing a proprietary biosynthesis
system for the manufacturing of pharmaceutical-grade cannabinoids,
as well as a pipeline of cannabinoid-based medications that target
diseases with high unmet medical needs. The Company is
dedicated to delivering new therapeutic alternatives to patients
that may benefit from cannabinoid-based medicines. For more
information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: developing a proprietary biosynthesis
platform technology for the manufacturing of pharmaceutical-grade
cannabinoids as well as a R&D pipeline of medications targeting
diseases with high unmet medical needs; presenting on a panel
discussion at the 31st Annual ROTH Conference; and
delivering new therapeutic alternatives to patients that may
benefit from cannabinoid-based medicines.
With respect to the forward-looking information contained in
this news release, InMed has made numerous assumptions regarding,
among other things: continued and timely positive preclinical and
clinical efficacy data; the speed of regulatory approvals; demand
for InMed's products; and continued economic and market stability.
While InMed considers these assumptions to be reasonable, these
assumptions are inherently subject to significant business,
economic, competitive, market and social uncertainties and
contingencies.
Additionally, there are known and unknown risk factors which
could cause InMed's actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
information contained herein. Known risk factors include, among
others: the presentation may not occur when planned, or at all;
clinical trials may not proceed as anticipated; economic or market
conditions may worsen; and InMed's proprietary biosynthesis
manufacturing process and drug development programs may not deliver
the expected level of results. A more complete discussion of the
risks and uncertainties facing InMed is disclosed in InMed's most
recent Annual Information Form and other continuous disclosure
filed with Canadian securities regulatory authorities on SEDAR at
www.sedar.com.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original
content:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-to-present-at-the-31st-annual-roth-conference-on-march-19-2019-300810399.html
SOURCE InMed Pharmaceuticals Inc.